Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence F Eichenfield

Showing results (251-260 of 376) with videos related to

Pageof 38
Sort By:
The British Journal of Dermatology|March 31, 2023
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)Antonio Torrelo, Barbara Rewerska, Maria Galimberti, et al.
Health and Quality of Life Outcomes|October 24, 2021
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitisJonathan I Silverberg, Amy DeLozier, Luna Sun, et al.
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Journal of Drugs in Dermatology : JDD|February 5, 2026
Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and SexJames Libecco, Lawrence F Eichenfield, Adelaide A Hebert, et al.
American Journal of Clinical Dermatology|May 15, 2023
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical StudyLawrence F Eichenfield, Richard G Gower, JinHua Xu, et al.
Journal of Pediatrics. Clinical Practice|February 14, 2025
Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group ConsensusMark Boguniewicz, Moise L Levy, Lawrence F Eichenfield, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Dermatology and Therapy|March 28, 2024
Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic DermatitisLawrence F Eichenfield, Linda F Stein Gold, Charles Lynde, et al.
Journal of the American Academy of Dermatology|September 1, 2023
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trialsLinda Stein Gold, Edward Lain, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD|June 19, 2020
Treatment of Impetigo in the Pediatric Population: Consensus and Future DirectionsLawrence A Schachner, Antonio Torrelo, Ayman Grada, et al.
Pageof 38

Showing results (251-260 of 376) with videos related to

Sort By:
Pageof 38
The British Journal of Dermatology|March 31, 2023
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)Antonio Torrelo, Barbara Rewerska, Maria Galimberti, et al.
Health and Quality of Life Outcomes|October 24, 2021
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitisJonathan I Silverberg, Amy DeLozier, Luna Sun, et al.
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Journal of Drugs in Dermatology : JDD|February 5, 2026
Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and SexJames Libecco, Lawrence F Eichenfield, Adelaide A Hebert, et al.
American Journal of Clinical Dermatology|May 15, 2023
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical StudyLawrence F Eichenfield, Richard G Gower, JinHua Xu, et al.
Journal of Pediatrics. Clinical Practice|February 14, 2025
Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group ConsensusMark Boguniewicz, Moise L Levy, Lawrence F Eichenfield, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Dermatology and Therapy|March 28, 2024
Maintenance of Investigator's Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic DermatitisLawrence F Eichenfield, Linda F Stein Gold, Charles Lynde, et al.
Journal of the American Academy of Dermatology|September 1, 2023
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trialsLinda Stein Gold, Edward Lain, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD|June 19, 2020
Treatment of Impetigo in the Pediatric Population: Consensus and Future DirectionsLawrence A Schachner, Antonio Torrelo, Ayman Grada, et al.
Pageof 38